Abstract | PURPOSE: METHODS: RESULTS: Of the 60 patients enrolled, two were not included in the data analysis because of protocol violations leaving 30 patients in the 0.1 mg group and 28 in the 0.25 mg group. There were no differences in the VAS pain scores or the number of women requesting an opioid other than codeine between the two groups. The VAS pruritus scores in the 0.1 mg group were lower throughout the 24 hr (P < 0.001). Fewer women in the 0.1 mg group (4/30 vs 12/28) requested nalbuphine to treat itching (P = 0.018). Nausea scores were lower in the 0.1 mg group (P < 0.001). CONCLUSION:
|
Authors | T Yang, T W Breen, D Archer, G Fick |
Journal | Canadian journal of anaesthesia = Journal canadien d'anesthesie
(Can J Anaesth)
Vol. 46
Issue 9
Pg. 856-60
(Sep 1999)
ISSN: 0832-610X [Print] United States |
PMID | 10490154
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics, Opioid
- Anti-Inflammatory Agents, Non-Steroidal
- Naproxen
- Morphine
- Indomethacin
|
Topics |
- Adult
- Analgesics, Opioid
(administration & dosage, therapeutic use)
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Cesarean Section
- Female
- Humans
- Indomethacin
(therapeutic use)
- Injections, Spinal
- Morphine
(administration & dosage, therapeutic use)
- Naproxen
(therapeutic use)
- Pain Measurement
- Pain, Postoperative
(drug therapy)
|